| Literature DB >> 30865922 |
John A Thompson1, Bryan J Schneider2, Julie Brahmer3, Stephanie Andrews4, Philippe Armand5, Shailender Bhatia1, Lihua E Budde6, Luciano Costa7, Marianne Davies8, David Dunnington9, Marc S Ernstoff10, Matthew Frigault11, Brianna Hoffner12, Christopher J Hoimes13, Mario Lacouture14, Frederick Locke4, Matthew Lunning15, Nisha A Mohindra16, Jarushka Naidoo3, Anthony J Olszanski17, Olalekan Oluwole18, Sandip P Patel19, Sunil Reddy20, Mabel Ryder21, Bianca Santomasso14, Scott Shofer22, Jeffrey A Sosman16, Momen Wahidi22, Yinghong Wang23, Alyse Johnson-Chilla24, Jillian L Scavone24.
Abstract
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.Entities:
Mesh：
Substances：
Year: 2019 PMID： 30865922 DOI： 10.6004/jnccn.2019.0013
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908